ImmunoScape wins Emerging Enterprise Award 2020
ImmunoScape won Singapore’s most prestigious Emerging Enterprise Award organized by Business Times and OCBC Bank. Emerging Enterprise Award honors the bold ambition of Singapore’s young businesses. It is a celebration of business innovation, resilience and excellence in SMEs. The award is for “demonstrating an enterprising mindset and displaying potential for significant and sustainable growth”. Click here […]
In the fight against COVID-19, ImmunoScape is joining forces with Dr. Patrick Reeves, Team Leader at the Massachusetts General Hospital Vaccine & Immunotherapy Center, using its signature assay, TargetScape, to perform high-dimensional immune profiling of COVID-19 induced changes across immune populations and phenotypes with a focus on antigen-specific T cells. The study will investigate the […]
As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is […]
ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC
The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines
ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology Using T-Cell Immune Response Profiling Platform
ImmunoScape studying immune response to Covid-19
The Straits Times recently interviewed ImmunoScape executives to learn about their current global collaborations to help understand the immune response to Covid-19 and how they can aid vaccine development.
ImmunoScape at LJI
ImmunoScape has established an on-site presence at La Jolla Institute of Immunology to support the research needs of their scientists. ImmunoScape provides high dimensional immune profiling using mass cytometry and their proprietary know-how, including tetramer multiplexing technology.
Dr Patrick Reeves at the Massachusetts General Hospital is collaborating with ImmunoScape on a pilot study to evaluate flu-specific T cell responses induced in participants taking part in a clinical trial of FluGen’s novel M2SR influenza vaccine using mass cytometry.
Prof. Hideho Okada at the University of California San Francisco is collaborating with ImmunoScape on a study to evaluate the vaccine-specific T cell response induced by a rationally designed vaccine administered to a targeted group of patients with WHO grade II glioma, a form of brain cancer that often progresses into an aggressive high-grade glioma, […]